| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ADGM | Common Stock | Award | +64.2K | +0.67% | 9.68M | Jan 22, 2025 | Direct | F1, F2 | ||
| holding | ADGM | Common Stock | 201K | Jan 22, 2025 | See footnote | F3 |
| Id | Content |
|---|---|
| F1 | On January 22, 2025, the Reporting Persons were issued 64,167 shares of Common Stock of the Issuer at a price of $2.00 per share pursuant to the terms of the Convert Waiver, dated December 26, 2024, by and between the Issuer and the Reporting Persons in exchange for the waiver by the Reporting Persons of certain rights related to the Issuer's default under its Senior Secured Convertible Notes. |
| F2 | The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of the Master Fund. Joseph Edelman ("Mr. Edelman") serves as the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of their indirect pecuniary interest therein, and this report shall not be deemed an admission that the Advisor or Mr. Edelman are beneficial owner of such securities for purposes of Section 16 or for any other purposes. |
| F3 | Directly held by C2 Life Sciences LLC ("C2"). The Advisor serves as the investment manager to C2. |